

committee. The applicant will be responsible for providing assurance in accordance with the appropriate guidelines and form provided in the application kit.

In addition to other applicable committees, Indian Health Service (IHS) institutional review committees also must review the project if any component of IHS will be involved or will support the research. If any American Indian community is involved, its tribal government must also approve that portion of the project applicable to it.

Application Submission and Deadline

The original and two copies of the application PHS Form 5161-1 (Revised 7/92, OMB Number 0937-0189) must be submitted to Henry S. Cassell, III, Grants Management Officer, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), 255 East Paces Ferry Road, NE., Room 300, Mailstop E-13, Atlanta, GA 30305, on or before July 26, 1995.

1. Deadline: Applications shall be considered as meeting the deadline if they are either:

(a) Received on or before the deadline date; or

(b) Sent on or before the deadline date and received in time for submission to the objective review group. (Applicants must request a legibly dated U.S. Postal Service postmark or obtain a legibly dated receipt from a commercial carrier or U.S. Postal Service. Private metered postmarks shall not be acceptable as proof of timely mailing.)

2. Late Applications: Applications which do not meet the criteria in 1.(a) or 1.(b) above are considered late applications. Late applications will not be considered in the current competition and will be returned to the applicant.

Where To Obtain Additional Information

A complete program description and information on application procedures are contained in the application package. Business management technical assistance may be obtained from Oppie Byrd, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), 255 East Paces Ferry Road, NE., Room 300, Mailstop E-13, Atlanta, GA 30305, telephone (404) 842-6546.

Programmatic technical assistance may be obtained from Joseph Cocalis, National Institute for Occupational Safety and Health, Centers for Disease and Control Prevention (CDC), 1095

Willowdale Road, Mailstop H-120, Morgantown, WV 26505-2888, telephone (304) 285-5754.

Please refer to Announcement 571 when requesting information and submitting an application.

Potential applicants may obtain a copy of Healthy People 2000 (Full Report, Stock No. 017-001-00474-0) or Healthy People 2000 (Summary Report, Stock No. 017-001-00473-1) referenced in the Introduction Section through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325, telephone (202) 512-1800.

Dated: June 8, 1995.

Diane D. Porter,

Acting Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95-14492 Filed 6-13-95; 8:45 am]

BILLING CODE 4163-19-P

Electronic Filing of Part 84 Respirator Approval and Certification Applications; Meetings

The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) announces the following meeting.

Name: Electronic Filing of Part 84 Respirator Approval and Certification Applications.

Date: Thursday, June 29, 1995; Friday, June 30, 1995, 8 a.m.-3:30 p.m., NIOSH Facility, 1095 Willowdale Road, Room 138, Morgantown, West Virginia 26505.

Time: 8 a.m.-3:30 p.m.

Place: Lakeview Resort & Conference Center, Governor's Ball, Rooms 1-3, Morgantown, West Virginia 26505.

Status: Open to the public, limited only by the space available.

Purpose: NIOSH has authority to certify respiratory protective equipment under 42 CFR 84. The purpose of this meeting is to review recent program improvements to initiate electronic application procedures for respirator certification and to demonstrate NIOSH software and requirements for electronic filing.

NIOSH has determined that savings and improved efficiency will be achieved by both NIOSH and manufacturers when an electronic application submittal process is available. Changes in the new 42 CFR Part 84 respirator approval application requirements also will be reviewed and program developments related to approval labels and engineering drawings required in the approval application will be discussed.

Contact Person for Additional Information: John M. Dower, NIOSH, CDC, 1095 Willowdale Road, Mailstop P04/1138, Morgantown, West Virginia 26505-2888, telephone 304/285-5954 or 5907.

Dated: June 8, 1995.

Julia M. Fuller,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95-14493 Filed 6-13-95; 8:45 am]

BILLING CODE 4163-19-M

Injury Research Grant Review Committee; Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: Injury Research Grant Review Committee (IRGRC).

Time and Date: 9 a.m.-5 p.m., July 10, 1995.

Place: Hotel Sofitel Chicago, 5550 North River Road, Rosemont, Illinois 60018.

Status: Open: 9 a.m.-9:20 a.m., July 10, 1995. Closed: 9:20 a.m.-5 p.m., July 10, 1995.

Purpose: This committee is charged with advising the Secretary of Health and Human Services, the Assistant Secretary for Health, and the Director, CDC, regarding the scientific merit and technical feasibility of grant applications relating to the support of injury control research program projects.

Matters To Be Discussed: Agenda items for the meeting will include announcements, discussion of review procedures, future meeting dates, and review of grant applications.

Beginning at 9:20 a.m., through 5 p.m., July 10, the committee will meet to conduct a review of grant applications. This portion of the meeting will be closed to the public in accordance with provisions set forth in section 552b(c) (4) and (6), title 5 U.S.C., and the Determination of the Associate Director for Management and Operations, CDC, pursuant to Public Law 92-463.

Agenda items are subject to change as priorities dictate.

Contact Person For More Information: Richard W. Sattin, M.D., Executive Secretary, IRGRC, National Center for Injury Prevention and Control, CDC, 4770 Buford Highway, NE, Mailstop K58, Atlanta, Georgia 30341-3724, telephone 404/488-4580.

Dated June 8, 1995.

Julia M. Fuller,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95-14494 Filed 6-13-95; 8:45 am]

BILLING CODE 4163-18-M

Food and Drug Administration

[Docket No. 95F-0111]

Lonza, Inc.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Lonza, Inc., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of a mixture of 1-bromo-3-chloro-5,5-dimethylhydantoin; 1,3-dichloro-5,5-dimethylhydantoin; and 1,3-dichloro-5-ethyl-5-methylhydantoin as a slimicide in the manufacture of paper and paperboard intended to contact food.

DATES: Written comments on the petitioner's environmental assessment by July 14, 1995.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Mitchell A. Cheeseman, Center for Food Safety and Applied Nutrition (HFS-217), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-418-3083.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 3B4382) has been filed by Lonza, Inc., c/o Delta Analytical Corp., 7910 Woodmont Ave., Bethesda, MD 20814. The petition proposes to amend the food additive regulations in § 176.300 *Slimicides* (21 CFR 176.300) to provide for the safe use of a mixture of 1-bromo-3-chloro-5,5-dimethylhydantoin; 1,3-dichloro-5,5-dimethylhydantoin; and 1,3-dichloro-5-ethyl-5-methylhydantoin as a slimicide in the manufacture of paper and paperboard intended to contact food.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4 (b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before July 14, 1995, submit to the Docket Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m.,

Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the **Federal Register**. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: May 24, 1995.

Alan M. Rulis,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 95-14463 Filed 6-13-95; 8:45 am]

BILLING CODE 4160-01-F

National Institutes of Health

Division of Research Grants; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meetings:

Purpose/Agenda: To review individual grant applications

Name of SEP: Clinical Sciences.

Date: June 25, 1995.

Time: 1:00 p.m.

Place: NIH, Rockledge II, Room 4140 Telephone Conference.

Contact Person: Dr. Larry Pinkus, Scientific Review Administrator, 6701 Rockledge Drive, Room 4140, Bethesda, MD 20892, (301) 435-1214.

Name of SEP: Clinical Sciences.

Date: June 26, 1995.

Time: 1:30 p.m.

Place: NIH, Rockledge II, Room 4140 Telephone Conference.

Contact Person: Dr. Larry Pinkus, Scientific Review Administrator, 6701 Rockledge Drive, Room 4140, Bethesda, MD 20892, (301) 435-1214.

Purpose/Agenda: To review Small Business Innovation Research Program grant applications.

Name of SEP: Multidisciplinary Sciences.

Date: July 10-11, 1995.

Time: 1:00 p.m.

Place: Crowne Plaza, Rockville, MD.

Contact Person: Dr. Harish Chopra, Scientific Review Admin., 6701 Rockledge Drive, Room 5112, Bethesda, MD 20892, (301) 435-51160.

The meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as

patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the grant review cycle.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: June 7, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95-14535 Filed 6-13-95; 8:45 am]

BILLING CODE 4140-01-M

National Institutes of Health; National Cancer Institute; Notice of Closed Meetings

Pursuant to Sec. 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings:

Purpose/Agenda: Review, discussion and evaluation of individual grant applications.

Committee Name: Subcommittee B of the Cancer Research Manpower and Education Review Committee.

Contact Person: Dr. Neil B. West, Room 611D, Executive Plaza North, 6130 Executive Blvd., Bethesda, MD 20892, Telephone: (301) 402-2785.

Date of Meeting: June 20-21, 1995.

Place of Meeting: The Georgetown Inn, 1310 Wisconsin Avenue, NW., Washington, DC 20007.

Time: 8 a.m.

Committee Name: Subcommittee D of the Cancer Centers and Research Programs Review Committee.

Contact Person: Dr. John Abrell, Room 635B, Executive Plaza North, 6130 Executive Blvd., Bethesda, MD 20892, Telephone: (301) 496-9767.

Date of Meeting: July 31-August 1, 1995.

Place of Meeting: Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, MD 20814.

Time: 8 a.m.

Committee Name: Subcommittee A of the Cancer Centers and Research Programs Review Committee.

Contact Person: Dr. David E. Maslow, Room 643A, Executive Plaza North, 6130 Executive Blvd., Bethesda, MD 20892, Telephone: (301) 496-2330.

Date of Meeting: August 3-4, 1995.

Place of Meeting: Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, MD 20814.

Time: 8 a.m.

The meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable